The arena of multiple sclerosis (MS) treatment has changed substantially over the past 20 years. Now nine different agents are approved for use in MS with several different routes of administration, safety characteristics and efficacy profiles. For the clinician and patient the availability of agents means greater flexibility and chances of disease control. However the expansion of options has also made the treatment of MS an increasingly complex field. This book is intended to help the general neurologist, internist and pharmaceutical industry agent to quickly become familiar with the current and future options for treating relapsing forms of MS.